设为首页加入收藏
  • 首页
  • Start up
  • 当前位置:首页 >Start up >【】

    【】

    发布时间:2025-09-13 09:03:08 来源:都市天下脉观察 作者:Start up

    Latest

    AI

    Amazon

    Apps

    Biotech & Health

    Climate

    Cloud Computing

    Commerce

    Crypto

    Enterprise

    EVs

    Fintech

    Fundraising

    Gadgets

    Gaming

    Google

    Government & Policy

    Hardware

    Instagram

    Layoffs

    Media & Entertainment

    Meta

    Microsoft

    Privacy

    Robotics

    Security

    Social

    Space

    Startups

    TikTok

    Transportation

    Venture

    More from TechCrunch

    Staff

    Events

    Startup Battlefield

    StrictlyVC

    Newsletters

    Podcasts

    Videos

    Partner Content

    TechCrunch Brand Studio

    Crunchboard

    Contact Us

    Image Credits:Andriy Onufriyenko / Getty Images
    Biotech & Health

    Pluton Biosciences takes its carbon-fixing microbes to market with a fresh $16.6M

    Devin Coldewey 10:40 AM PDT · May 30, 2023

    Pluton Biosciences is hard at work identifying beneficial microorganisms and putting them to work in agriculture, and just raised a $16.5 million Series A round to commercialize its most promising finds.

    The company raised its $6.6 million seed round in 2021, and I reported then about its approach of identifying and isolating microbes and bacteria that perform useful work. Nature is pretty good at solving problems via billions of years of evolution, and there’s tremendous biodiversity in every scoop of soil or microbiome.

    As cool as it is to isolate and study dozens of new-to-science micros, ultimately Pluton needed to choose one that worked as product, not just a project. They settled on what they call a “microbial cover crop” that captures and sequesters carbon and nitrogen in the soil. This process is not just good for the crops and the environment, but it’s also potentially a very valuable market; Pivot Bio raised a monster $430 million in 2021 to commercialize a microbial alternative to nitrogen-filled fertilizer.

    “We have highly repeatable lab and greenhouse data for several product candidates that sequester carbon and nitrogen from the atmosphere and place it in the soil. Early testing verified growth on soil during the target season on agricultural fields,” said CEO and CFO Elizabeth Gallegos in response to TechCrunch’s questions. Field testing this year should quantify the sequestration process and how the product  affects (positively, presumably) the soil itself.

    Meanwhile, R&D continues, along the carbon side and the more generally environment-friendly:

    “We have discovered novel microbes that generate durable carbon that will persist in soils for decades and have the potential to be used in industries outside of agriculture,” Gallegos said. And one of their microbes led them to discover a new molecule that acts as an insecticide against a particular pest, the fall armyworm — that may be their next big product.

    The company has doubled in size from 8 to 17 people, and expects to double again over the next year; the physical size of their office and lab has also doubled, and one expects it will continue to grow as well.

    Techcrunch event

    Join 10k+ tech and VC leaders for growth and connections at Disrupt 2025

    Netflix, Box, a16z, ElevenLabs, Wayve, Sequoia Capital, Elad Gil — just some of the 250+ heavy hitters leading 200+ sessions designed to deliver the insights that fuel startup growth and sharpen your edge. Don’t miss the 20th anniversary of TechCrunch, and a chance to learn from the top voices in tech. Grab your ticket before Sept 26 to save up to $668.

    Join 10k+ tech and VC leaders for growth and connections at Disrupt 2025

    Netflix, Box, a16z, ElevenLabs, Wayve, Sequoia Capital, Elad Gil — just some of the 250+ heavy hitters leading 200+ sessions designed to deliver the insights that fuel startup growth and sharpen your edge. Don’t miss the 20th anniversary of TechCrunch, and a chance to learn from the top voices in tech. Grab your ticket before Sept 26 to save up to $668.

    San Francisco | October 27-29, 2025 REGISTER NOW

    The new funding round was led by Illumina Ventures and RA Capital, which tend to focus on genomics, precision health, and other life science verticals. Fall Line Capital, the Grantham Foundation, First In Ventures, Wollemi, Radicle Growth, and iSelect also participated in the raise.

    Puna Bio’s extremophile microbe menagerie survives and revives depleted soil

    • 上一篇:16 months after its IPO, UK online retailer Made.com prepares for administration
    • 下一篇:Despite myriad flaws, US remains top spot for Black startup founders seeking VC dollars

      相关文章

      • Brightflow AI aims to spotlight small business cash flow
      • Meet these five emerging startups at TC Sessions: Crypto
      • Disrupt kicks off tomorrow — check out the highlights
      • Q3 data reminds us that venture debt is not a Hail Mary
      • Ring launches pilot program to let local agencies share updates and 'safety information'
      • V3 Ventures launches to put €100M into startups in health, beauty and food
      • Former VC brings smart financial advice to people who really need it, instead of just the rich
      • The highs and lows of Q3 venture capital data for women startup founders
      • Why startups are better off prioritizing growth instead of optimizing cloud costs
      • Nigeria’s AltSchool increases course options amidst soaring tech

        随便看看

      • See you in Boston for TechCrunch's Annual Founder Summit
      • Daily Crunch: Mobile gaming review — Playing on the Logitech G Cloud with Shadow
      • Uils wants to lend LatAm's rideshare drivers cash based on their driving record
      • Announcing the TechCrunch Startup Battlefield 20 companies on the Disrupt Stage
      • Which Instagram ad placement is more cost
      • Don’t miss our partner breakouts and Discovery stage sessions at Disrupt
      • AI chip startup Axelera lands $27M in capital to commercialize its hardware
      • Sample Seed pitch deck: Supliful's $1m deck
      • 6 investors discuss why AI is more than just a buzzword in biotech
      • Q3 data reminds us that venture debt is not a Hail Mary
      • Copyright © 2025 Powered by 【】,都市天下脉观察   辽ICP备198741324484号sitemap